A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma

Abstract

Many driver pathways for cancer cell proliferation have been reported. Driver pathway activation is often evaluated based on a single hotspot mutation such as EGFR L858R. However, because of complex intratumoral networks, the impact of a driver pathway cannot be predicted based on only a single gene mutation. Here, we developed a novel diagnostic system named the "eGfR impact score" which is based on multiplex mRNA expression profiles, which can predict the impact of the EGFR pathway in lung cancer cells and the effect of EGFR-tyrosine kinase inhibitors on malignancy. The EGFR impact score indicated robust predictive power for the prognosis of early-stage lung cancer because this score can evaluate the impact of the eGfR pathway on the tumor and genomic instability. Additionally, the molecular features of the poor prognostic group resembled those of biomarkers associated with immune checkpoint inhibitors. the eGfR impact score is a novel prognostic and therapeutic indicator for lung adenocarcinoma.

Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types

“…Supporting the notion of distinguished EGFR and fusion aberrations, our transcriptomic analysis demonstrated that MPE-derived cell lines were subtyped in parallel with the genetic aberrations. The transcriptomic subtyping of EGFR-mutant NSCLC has been performed in other studies as well 28 , 29 . Our study has demonstrated that MPE-derived NSCLC cell lines also retain the transcriptional characteristics of EGFR-mutant NSCLC, which were distinctive to NSCLC cell lines with other driver mutations such as KRAS or fusion genes.…”